Michael Raab - Amicus Therapeutics Independent Director
| FOLD Stock | USD 10.61 0.28 2.71% |
Director
Mr. Michael G. Raab is Lead Independent Director of Amicus Therapeutics, Inc. Mr. Raab has served as President and Chief Executive Officer of Ardelyx, Inc. since March 2009. Mr. Raab previously served as a partner of New Enterprise Associates from June 2002 until December 2008, with a focus on healthcare investing. From 1999 to 2002, he was Senior Vice President, Therapeutics and General Manager, Renagel at Genzyme Corporationrationration. Mr. Raab currently serves as a member of the Board of Directors of Ardelyx, Inc since 2018.
| Age | 53 |
| Tenure | 6 years |
| Address | 47 Hulfish Street, Princeton, NJ, United States, 08542 |
| Phone | 609 662 2000 |
| Web | https://amicusrx.com |
Michael Raab Latest Insider Activity
Tracking and analyzing the buying and selling activities of Michael Raab against Amicus Therapeutics stock is an integral part of due diligence when investing in Amicus Therapeutics. Michael Raab insider activity provides valuable insight into whether Amicus Therapeutics is net buyers or sellers over its current business cycle. Note, Amicus Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Amicus Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Michael Raab few days ago Disposition of 7500 shares by Michael Raab of Ardelyx at 7.0565 subject to Rule 16b-3 | ||
Michael Raab over two weeks ago Disposition of 1518 shares by Michael Raab of Ardelyx at 7.31 subject to Rule 16b-3 |
Amicus Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.0612) % which means that it has lost $0.0612 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0704) %, meaning that it created substantial loss on money invested by shareholders. Amicus Therapeutics' management efficiency ratios could be used to measure how well Amicus Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of April 19, 2024, Return On Tangible Assets is expected to decline to -0.28. In addition to that, Return On Capital Employed is expected to decline to -0.13. At present, Amicus Therapeutics' Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Intangibles To Total Assets is expected to grow to 0.39, whereas Other Assets are forecasted to decline to about 41.8 M.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| JeanJacques Bienaime | Incyte | 64 | |
| Debbie Allen | argenx NV ADR | 57 | |
| Steve Krognes | Denali Therapeutics | 56 | |
| Paul Clancy | Agios Pharm | 56 | |
| Daniel Welch | Ultragenyx | 60 | |
| Mary Szela | Kura Oncology | 55 | |
| Kathryn Falberg | Biomarin Pharmaceutical | 54 | |
| Steven Stein | Kura Oncology | 51 | |
| Lewis Cantley | Agios Pharm | 75 | |
| Wendy Dixon | Incyte | 62 | |
| Lynne Parshall | Cytokinetics | 64 | |
| Jacqualyn Fouse | Agios Pharm | 56 | |
| Paul Clancy | Incyte | 56 | |
| Lonnel Coats | Blueprint Medicines Corp | 53 | |
| Mark Goldberg | Blueprint Medicines Corp | 63 | |
| Santo Costa | Cytokinetics | 73 | |
| Robert Califf | Cytokinetics | 66 | |
| Paul Blackburn | Mereo BioPharma Group | 61 | |
| Kaye FosterCheek | Agios Pharm | 58 | |
| Jakob Loven | Arvinas | 40 | |
| Thilo Schroeder | Blueprint Medicines Corp | 32 | |
Management Performance
| Return On Equity | -1.07 | ||||
| Return On Asset | -0.0612 |
Amicus Therapeutics Leadership Team
Elected by the shareholders, the Amicus Therapeutics' board of directors comprises two types of representatives: Amicus Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Amicus. The board's role is to monitor Amicus Therapeutics' management team and ensure that shareholders' interests are well served. Amicus Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Amicus Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Hung Do, Senior Vice President - Discovery Biology | ||
| Robert Essner, Independent Director | ||
| John Kirk, Vice President - Regulatory Affairs | ||
| David Clark, Chief Officer | ||
| Andrew Mulberg, Vice President - Regulatory Strategy | ||
| Craig Wheeler, Independent Director | ||
| Daphne Quimi, Principal Accounting Officer, VP of Fin. and Corporate Controller | ||
| Bradley Campbell, Pres and COO | ||
| Burke Whitman, Independent Director | ||
| Enrique Dilone, Vice President - Technical Operations | ||
| John Crowley, Executive Chairman | ||
| Dipal Doshi, Senior Vice President - Business Planning and Development | ||
| Mark Baldry, Vice President of Global Marketing | ||
| Margaret McGlynn, Independent Director | ||
| Samantha Prout, Principal Accounting Officer, Controller | ||
| Bradley MBA, President CEO | ||
| Andrew Faughnan, Director Relations | ||
| Diana Moore, Head Communications | ||
| Kenneth Peist, Vice President - Legal and Intellectual Property | ||
| Ken Valenzano, Senior Vice President - Preclinical Research | ||
| Ted Love, Independent Director | ||
| Jay Barth, Chief Medical Officer | ||
| Jayne Gershkowitz, Vice President - Patient Advocacy & Public Policy | ||
| Donald Hayden, Lead Independent Director | ||
| Patrik Esq, Global Officer | ||
| Michael Raab, Independent Director | ||
| Sara Pellegrino, IR Contact Officer | ||
| Willem Weperen, Regional Vice President and Country Manager, International | ||
| Sol Barer, Independent Director | ||
| Julie Yu, Vice President - Clinical Operations and Data Management | ||
| Patrik Florencio, Global VP | ||
| William Baird, CFO | ||
| David Allsop, Senior Vice President - International | ||
| Lynn Bleil, Independent Director | ||
| Simon Harford, Chief Officer | ||
| Ellen Rosenberg, General Counsel and Corporate Secretary | ||
| Simon Jordan, Senior Vice President - International | ||
| Jill Weimer, Senior Vice President of Discovery Research and Gene Therapy Science | ||
| Glenn Sblendorio, Independent Director | ||
| Jeffrey Castelli, Vice President - Program and Portfolio Management | ||
| Kurt Andrews, Senior Vice President - Human Resources |
Amicus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Amicus Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.07 | ||||
| Return On Asset | -0.0612 | ||||
| Profit Margin | (0.38) % | ||||
| Operating Margin | (0.03) % | ||||
| Current Valuation | 3.21 B | ||||
| Shares Outstanding | 295.38 M | ||||
| Shares Owned By Insiders | 0.75 % | ||||
| Shares Owned By Institutions | 99.25 % | ||||
| Number Of Shares Shorted | 32.49 M | ||||
| Price To Earning | (9.18) X |
Amicus Therapeutics Investors Sentiment
The influence of Amicus Therapeutics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Amicus. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Amicus Therapeutics' public news can be used to forecast risks associated with an investment in Amicus. The trend in average sentiment can be used to explain how an investor holding Amicus can time the market purely based on public headlines and social activities around Amicus Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Amicus Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Amicus Therapeutics' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Amicus Therapeutics' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Amicus Therapeutics.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Amicus Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Amicus Therapeutics' short interest history, or implied volatility extrapolated from Amicus Therapeutics options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Amicus Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Amicus Stock refer to our How to Trade Amicus Stock guide.You can also try the AI Investment Finder module to use AI to screen and filter profitable investment opportunities.
Complementary Tools for Amicus Stock analysis
When running Amicus Therapeutics' price analysis, check to measure Amicus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amicus Therapeutics is operating at the current time. Most of Amicus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Amicus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amicus Therapeutics' price. Additionally, you may evaluate how the addition of Amicus Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |
Is Amicus Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amicus Therapeutics. If investors know Amicus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amicus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.51) | Revenue Per Share 1.353 | Quarterly Revenue Growth 0.306 | Return On Assets (0.06) | Return On Equity (1.07) |
The market value of Amicus Therapeutics is measured differently than its book value, which is the value of Amicus that is recorded on the company's balance sheet. Investors also form their own opinion of Amicus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Amicus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amicus Therapeutics' market value can be influenced by many factors that don't directly affect Amicus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amicus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amicus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amicus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.